Skip to content
10-Q

Quarterly Report

Annovis Bio, Inc. ANVS

0001104659-26-062626

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 34.65M sh
Shares Diluted Q1 2026 · Mar 31, 2026 27.85M sh
Shares Diluted Q1 2026 · Mar 31, 2025 17.43M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$9.01M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.1M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.22M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $19.53M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.13M
Stockholders Equity Q1 2026 · Dec 31, 2025 $16.85M
Stockholders Equity Q1 2026 · Mar 31, 2025 $24.05M
Stockholders Equity Q1 2026 · Dec 31, 2024 $9.31M
Current Liabilities Q1 2026 · Mar 31, 2026 $12.79M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.64M
Total Liabilities Q1 2026 · Mar 31, 2026 $13.12M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.23M
Total Assets Q1 2026 · Mar 31, 2026 $16.24M
Total Assets Q1 2026 · Dec 31, 2025 $21.08M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.63
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.32
Eps Basic Q1 2026 · Mar 31, 2026 −$0.63
Eps Basic Q1 2026 · Mar 31, 2025 −$0.32
Sga Expense Q1 2026 · Mar 31, 2026 $1.29M
Sga Expense Q1 2026 · Mar 31, 2025 $1.27M
Rd Expense Q1 2026 · Mar 31, 2026 $16.72M
Rd Expense Q1 2026 · Mar 31, 2025 $5.01M
Net Income Q1 2026 · Mar 31, 2026 −$17.61M
Net Income Q1 2026 · Mar 31, 2025 −$5.54M
Operating Income Q1 2026 · Mar 31, 2026 −$18.01M
Operating Income Q1 2026 · Mar 31, 2025 −$6.28M
Revenue Q1 2026 · Mar 31, 2026 $0